Carregant...

Linagliptin: A thorough Characterization beyond Its Clinical Efficacy

Linagliptin, one of the five dipeptidyl peptidase-4 inhibitors available, has recently entered the market both in the US and in most European countries for treatment of type 2 diabetes mellitus. It presents a xanthine-based structure, and is characterized by unique pharmacokinetics, with non-linear...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Sortino, Maria Angela, Sinagra, Tiziana, Canonico, Pier Luigi
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2013
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3581698/
https://ncbi.nlm.nih.gov/pubmed/23550180
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2013.00016
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!